- Gilead resubmits HIV drug application to FDA
- Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment
- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA opens dialogue of incorporating technology, pharmacy into switch paradigm
- FDA grants priority review to Gilead's Truvada for HIV prevention
FOSTER CITY, Calif. — The Food and Drug Administration has accepted a regulatory approval application from Gilead Sciences for a drug to treat HIV, the company said.
Gilead said the FDA planned to review the application for the Quad by Aug. 27.
The Quad combines four Gilead drugs — Truvada (emtricitabine and tenofovir disoproxil fumarate), cobicistat and elvitegravir — into one pill. The last drug was licensed from Japan Tobacco.